Medrx's share price rose approximately 181% in one week. Its initial U.S. shipment plans, the prospect of a launch this year and its past approval process have drawn attention as potential catalysts.
In the third week of November 2026, Medrx's share price surged. The stock closed in the high ¥30s on the 13th, then hit consecutive daily limit highs on the 19th and 20th, closing at ¥107 on the 20th. Market attention appears to be focused not on whether there have been new announcements but on two points disclosed on 30 October: that the initial U.S. shipment was scheduled for delivery to its sales partner in November, and that the product was expected to launch in 2026.
The drug discovery venture, headquartered in Higashikagawa, Kagawa Prefecture, develops transdermal formulations, commonly referred to as patches. Its strength lies in using ILTS technology to deliver drugs through the skin. Its first U.S.-bound product is Bondlido, a lidocaine patch for relieving postherpetic neuralgia. After three FDA approval deferrals, it received marketing approval in September 2025.
However, the company has limited experience generating revenue by selling products. Most of its revenue comes from milestones and research and development income from co-development partners, while actual product sales remain limited. The initial shipment is delivery to a partner's warehouse, which is different from prescriptions for U.S. patients or recurring orders from pharmacies. The formal execution of its current sales license agreement has not yet been completed, and its shares have been diluted each time it raises funds.
Points relevant to investment decisions include the sales structure after shipment, insurance coverage, the partner's distribution network and supply structure; the risks associated with U.S. drug pricing and distribution systems; and the indicators that should be checked with each earnings disclosure. The current situation is viewed as the company's key test, with the real contest beginning after shipment.